Diagnostics

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.

A new acquisition seems routine, but it's part of Principle Health's aggressive strategy to build a diagnostic empire for long-term care. Here's why.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

A crucial CAP accreditation for its advanced CNS cancer test positions Plus Therapeutics to unlock new markets and redefine patient care with precision diagnostics.

A new diagnostic tool, Delve Detect, is using metagenomic sequencing to unmask elusive pathogens in the brain, offering hope where conventional tests fail.

Scispot's Series A targets the messy 'coordination gap' in labs. It's a bet that before we get self-driving labs, we must first fix the data pipes.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

Zepto Life Technology's FDA Breakthrough status for a fungal test isn't just a win for patients; it's a strategic move in liquid biopsy's new frontier.

A new AI can detect Parkinson's progression where the current gold standard fails. In a stunning validation, the study was led by the very scientists who created the old method.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

Mindray's new Hepatus-Series goes beyond a simple product launch, integrating AI-driven elastography to transform GI diagnostics and challenging market norms.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

One year after its US launch, Pictor Holdings is gaining traction with a platform that makes complex disease testing fast, cheap, and accessible. But can its unique business model truly scale?

A new manufacturing deal sees Bluejay Diagnostics bet on U.S. resilience. It's a strategic retreat from global risk for a firm facing a long regulatory road.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

A Japanese firm has achieved a breakthrough in manufacturing ultra-smooth capillary tubes, a tiny component set to unlock major advances in medicine and tech.